The Effects of Psilocybin on Social Connectedness

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Loneliness, Grief

In brief

The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.

Key facts

Study ID

NCT07693153

Run by

Yale University

People needed

51

Starts

2026-08-31

Expected to finish

2031-12-15

Last updated by the study team

2026-07-09

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Medically healthy
• Ability to provide consent
• High loneliness defined by the UCLA-3 Loneliness Scale
• Willingness to comply with all study procedures and availability for the duration of the study

You may not qualify if…

• Any unstable medical condition, psychiatric disorder, or circumstance that, in the opinion of the investigator, could compromise participant safety, interfere with study participation, or hinder the participant's ability to comply with study procedures and requirements
• Positive pregnancy test or women who are breastfeeding
• Any contraindication to MRI such as a pacemaker or metal implants

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.